Close Menu

NEW YORK – Belgian drug developer Octimet Oncology said on Wednesday that it has exclusively licensed its lead clinical compound OMO-1 and another, unidentified preclinical-stage drug to Shanghai-based Allist Pharmaceuticals.

OMO-1, a selective MET kinase inhibitor, has demonstrated preliminary activity and safety as a single agent and in combination with an EGFR inhibitor in cancer patients with MET alterations in Europe. When MET is amplified in non-small cell lung cancers, it drives resistance to EGFR inhibitors.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.


NTRK fusions are oncogenic drivers in a variety of tumors.

Sponsored by

This webinar, Part 3 of the “Advances in RNA-based Biomarker Development for Precision Oncology” webinar series sponsored by GeneCentric Therapeutics, will discuss novel and emerging applications of RNA-based genomic analysis in precision oncology, form characterizing the tumor microenvironment to informing the development of immuno-oncology treatments.

Sponsored by

Circulating tumor DNA (ctDNA) can allow clinicians and researchers to better understand which patients are at high risk of recurrence and should be offered intensified chemotherapy or selected for clinical trials.


In non-small cell lung cancer (NSCLC), early detection of emerging resistance mutations such as EGFR T790M is important in order to determine the appropriate targeted therapeutic strategy.